Furthermore, studies have shown that SLC7A11 overexpression is associated with a poor prognosis in AML and that ferroptosis induction represents a novel treatment strategy [31,32,33,34,35,36]. This evidence concerns the gene SLC7A11 and acute myeloid leukemia.